

Polymerase synthesis of DNA labelled with benzylidene cyanoacetamide-based fluorescent molecular rotors: fluorescent light-up probes for DNA-binding proteins

Dmytro Dziuba,^a Radek Pohl^a and Michal Hocek^{a,b*}


^a *Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Gilead & IOCB Research Center, Flemingovo nam. 2, CZ-16610 Prague 6, Czech Republic. E-mail: hocek@uochb.cas.cz.*

^b *Department of Organic Chemistry, Faculty of Science, Charles University in Prague, Hlavova 8, CZ-12843 Prague 2, Czech Republic.*

Contents

A. Additional figures and tables	S2
B. List of abbreviations.....	S5
C. Chemical synthesis and characterization of fluorescent nucleosides and dNTPs.....	S6
D. Enzymatic incorporation of modified dNTPs into DNA	S13
E. UV-Vis and Fluorescence measurements	S16
F. References	S18
G. Copies of the NMR spectra.....	S19
H. Copies of MALDI spectra.....	S28

A. Additional figures and tables



Scheme S1. Chemical synthesis of the fluorescent molecular rotors. Reagents and conditions: i) malononitrile, piperidine, MeOH [ref. S1] ii) 1: 40°C, 7h; 2: 70°C, overnight. iii) DIMCARB, **I** or **II**, CHCl₃, r.t. 30–60 min. iv) **VI** or **VII**, PdCl₂(PPh₃)₂, CuI, NEt₃, DMF, 80°C, 1h. v) 1: POCl₃, PO(OCH₃)₃, 0°C, 2–4 h; 2: (n-Bu₃NH)₂H₂P₂O₇, NBu₃, DMF, 0°C, 1 h; 3: 1M TEAB, 5 min; 4: HPLC; 5: Dowex 50WX8 (Na⁺ cycle).




Figure S1. (a) PEX with modified dNTPs $\text{dC}^{\text{VJ}}\text{TP}$ (**4a**) and $\text{dC}^{\text{VDP}}\text{TP}$ (**4b**) performed by KOD XL DNA polymerase; primer **P3X** and template **T3X** were used, assuming incorporation of four modified dC^{X} residues (see Table S1 for sequences); P: primer; positive control: four natural dNTPs (lane 1); negative control: dATP, dGTP, dTTP (lane 2); modified dNTP **4a**: dATP, dGTP, dTTP and **4a** (lane 3); modified dNTP **4b**: dATP, dGTP, dTTP and **4b** (lane 4).

(b–c) MALDI analysis of DNA obtained by semi-preparative PEX with **4a** and **4b** followed by magnetic separation; primer **P3X** and biotinylated template **T3Xb** were used (Table S1); products incorporating dC^{VJ} and dC^{VDP} moieties are shown in figures (b) and (c), respectively; peak of the btm-template partially released from the beads during denaturation step was also observed.




Figure S2. UV-vis spectra of purified PEX products obtained after incubation of a reaction mixture containing $\text{dC}^{\text{VDP}}\text{TP}$, dATP, dTTP, dGTP, primer **P3X** and template **T3X** either with (black line) or without (red line) KOD XL DNA polymerase at 60°C for 30 min. The mixtures were purified using QIAquick Nucleotide Removal Kit (QIAGEN). The absence of long-wavelength absorption in the spectrum of the sample incubated without polymerase indicated that $\text{dC}^{\text{VDP}}\text{TP}$ does not bind unspecifically to DNA.

Table S1. Oligodeoxynucleotides used for enzymatic reactions

Name	Length (nt)	Sequence (5'→3') ^a	Used in
Primers			
P1X	25	GAA TTC GAT ATC AAG AGA CAT GCC T	PEX
P2X	15	TCA AGA GAC ATG CCT	PEX
P3X	15	CAT GGG CGG CAT GGG	PEX
P1N	19	CCG ATC TAG TGA GTC CTC G	NEAR
P1R	25	CAA GGA CAA AAT ACC TGT ATT CCT T	PCR
P2R	20	GAC ATC ATG AGA GAC ATC GC	PCR
Templates			
T1X	50	TAC CTT ATC CAT AAT AGA CAT GTC TAG GCA TGT CTC TTG ATA TCG AAT TC	PEX
T2Xb	30	btn ATA ATA GAC ATG TCT AGG CAT GTC TCT TGA	PEX
T3X	31	CTA GCA TGA GCT CAG TCC CAT GCC GCC CAT G	PEX
T3Xb	31	btn CTA GCA TGA GCT CAG TCC CAT GCC GCC CAT G	PEX
T1N	31	TCA ACT CAT GAC CGA GGA CTC ACT AGA TCG G	NEAR
T2N	31	TCA GCG TAG ACT CGA GGA CTC ACT AGA TCG G	NEAR
T1R	98	GAC ATC ATG AGA GAC ATC GCC TCT GGG CTA ATA GGA CTA CTT CTA ATC TGT AAG AGC AGA TCC CTG GAC AGG CAA GGA ATA CAG GTA TTT TGT CCT TG	PCR
Others			
L10	10	CAG TGA CTA G	ssDNA ladder ^{S6}
L20	20	CAG TGA CTA GCT TAC GGA CT	ssDNA ladder ^{S6}
L50	50	CAG TGC ATG ACT ATC GGA CCG TAT GAC TAG CTC AGG TAT CCA GTG ACT AG	ssDNA ladder ^{S6}

Footnotes: a) btn = 5'-biotin.

Table S2. Single-stranded modified DNA obtained by PEX and NEAR

#	Name	Sequence (5'→3') ^a	Obt. ^b	Prim/ Tmpl ^c	M _{calcd} ^d	M _{found} ^e
1	ON1	TCA AGA GAC ATG CCT AGA C^{VDP} AT GT C^{VDP} TAT TAT	PEX	P2X / T2Xb	9691	9693
2	ON2	P - GT C^{VJ} ATG AGT TGA	NEAR	P1N / T1N	4082	4083
3	ON3	P - GT C^{VDP} ATG AGT TGA	NEAR	P1N / T1N	4030	4031
4	ON4	P - AGT C^{VJ} TA C^{VJ} G^{VJ} TGA	NEAR	P1N / T2N	4633	4634
5	ON5	P - AGT C^{VDP} TA C^{VDP} G^{VDP} TGA	NEAR	P1N / T2N	4477	4479

Footnotes. a) P = 5' phosphate group; ODNs containing **dC^{VJ}** and **dC^{VDP}** were obtained using triphosphates **4a** and **4b**, respectively. b) Enzymatic reactions used for the synthesis. c) Primer / Template used (Table S1 for sequences). d) Molecular mass calculated using ChemBioDraw13 and OligoCalc.^{S7} e) *m/z* of the major peak in the MALDI-TOF spectrum; for copies of MALDI-TOF spectra see pages S28–S30 of the Supporting information.

B. List of abbreviations

BSA – Bovine serum albumin

DIMCARB – Dimethylammonium dimethylcarbamate

DMSO – Dimethyl sulfoxide

DTT – Dithiothreitol

EA – Ethyl acetate

EDTA – Ethylenediaminetetraacetic acid

EG – Ethylene glycol

FMR – Fluorescent molecular rotor

NEAR – Nicking enzyme amplification reaction

ODNs – Oligodeoxynucleotides

PAGE – Polyacrylamide gel electrophoresis

PBS – Phosphate buffered saline

PCR – Polymerase chain reaction

PEX – Primer extension

SSB – Single-strand Binding Protein from *Escherichia coli*

TBE – Tris borate – EDTA buffer

TEAA – Triethylammonium acetate buffer

TEAB – Triethylammonium bicarbonate buffer


TLC – Thin-layer chromatography

C. Chemical synthesis and characterization of fluorescent nucleosides and dNTPs

Materials and methods

Reagents and solvents were purchased from Sigma-Aldrich and AlfaAesar. 5-Iodo-2'-deoxycytidine (**VIII**) was purchased from Berry & Associates. 4-formyl julolidine (**I**) was synthesized according to the literature procedure.^{S2} Fluorescent molecular rotors **1a** and **1b** were synthesized as described by Theodorakis et al.^{S1} Column chromatography was performed by using silica gel (40–63 μm). Semi-preparative purification of **dC^XTPs** was performed by HPLC (Waters modular HPLC system) on a column packed with 10 μm C18 reversed phase (Phenomenex, Luna C18 (2) 100 \AA). NMR spectra were recorded on a 600 MHz (600.1 MHz for ^1H , 150.9 MHz for ^{13}C) or a 500 MHz (500.0 MHz for ^1H , 200.3 MHz for ^{31}P , 125.7 MHz for ^{13}C) spectrometer from sample solutions in CDCl_3 , D_2O or DMSO-d_6 . Chemical shifts (in ppm, δ scale) were referenced as follows: CDCl_3 solutions, ^1H referenced to TMS ($\delta = 0$ ppm), ^{13}C referenced to the solvent signal ($\delta = 77.0$ ppm); DMSO-d_6 solutions, ^1H referenced to the residual solvent signal ($\delta = 2.50$ ppm), ^{13}C referenced to the solvent signal ($\delta = 39.7$ ppm); D_2O solutions, referenced to 1,4-dioxane as an internal standard ($\delta(^1\text{H}) = 3.75$ ppm, $\delta(^{13}\text{C}) = 69.3$ ppm). ^{31}P NMR spectra were referenced to the phosphate buffer signal ($\delta = 2.35$ ppm). Coupling constants (J) are given in Hz. NMR spectra of dNTPs were measured in phosphate buffer at $\text{pD} = 7.1$. Complete assignment of all NMR signals was achieved by using a combination of H,H-COSY, H,C-HSQC, and H,C-HMBC experiments. High resolution mass spectra were measured on a LTQ Orbitrap XL (Thermo Fisher Scientific) spectrometer using ESI ionization.


N-Propargyl-cyanoacetamide (**V**)



N-Propargyl-cyanoacetamide (**V**) was synthesized using the literature procedure^{S3} with minor modifications. A mixture of ethyl cyanoacetate **IV** (10 mL) and propargyl amine **III** (9 mL) was heated for 7 hours at 40 °C and then overnight at 70°C. The dark-red solid obtained was recrystallized from a minimal volume of methanol and washed with dichloromethane to give the product as pale-brown solid (8.14g, 71%). M.p. (MeOH) 107 – 108 °C (lit.^{S3} 100 – 103 °C) ^1H NMR (500.0 MHz, DMSO-d_6): 3.18 (t, 1H, $^4J = 2.5$, $\text{HC}\equiv\text{C-}$); 3.67 (s, 2H, CH_2CN); 3.89 (dd, 2H, $^3J = 5.4$, $^4J = 2.5$,

CH₂N); 8.70 (bt, 1H, ³J = 5.4, NH). ¹³C NMR (125.7 MHz, DMSO-*d*₆): 25.35 (CH₂CN); 28.66 (CH₂N); 73.81 (HC≡C-); 80.51 (-C≡CH); 116.17 (CN); 162.26 (CO). Anal. calcd for C₆H₆N₂O: C, 59.01; H, 4.95; N, 22.94. Found: C, 58.79; H, 4.88; N, 22.69.


General procedure for the Knoevenagel condensation of *N*-propargyl-cyanoacetamide (V) with *p*-dialkylaminobenzaldehydes catalyzed by DIMCARB^{S4-S5}



Dimethylammonium dimethylcarbamate (DIMCARB, 3.85 mL, 30 mmol) was added to a solution of corresponding aldehyde (5 mmol) in chloroform (8 mL) and the mixture was stirred for 10 – 15 min at ambient temperature. Then, *N*-propargyl-cyanoacetamide **V** (732 mg, 6 mmol) was added at once. The mixture was stirred at room temperature for 30 – 60 minutes until the complete consumption of the starting aldehyde as detected by TLC (hexane/EA, 7/3). Then, ~2N HCl (50 mL) was slowly added to the reaction flask and the resulting mixture was stirred until the evolution of gas stopped. Organic phase was separated; the water phase was extracted with dichloromethane (3×); the combined organic layers were dried over MgSO₄, concentrated on a rotavap and purified by column chromatography eluted consequently with ethyl acetate in hexane (20→30%), then with hexane, and finally with acetone in dichloromethane (0→4%) to give the corresponding acetylene-containing molecular rotors **VI** or **VII**.

(*E*)-2-Cyano-*N*-(prop-2-yn-1-yl)-3-(julolidine-9-yl)acrylamide (VI)

Orange solid (1.29 g, 85%) was obtained following the general procedure. *R*_f = 0.30 (hexane/ethyl acetate, 7/3) ¹H NMR (500.0 MHz, CDCl₃): 1.96 (m, 4H, H-3,6-julolidine); 2.27 (t, 1H, ⁴J = 2.5, HC≡C); 2.75 (m, 4H, H-4,5-julolidine); 3.31 (m, 4H, H-2,7-julolidine); 4.19 (dd, 2H, ³J = 5.3, ⁴J = 2.5, CH₂N); 6.37 (bt, 1H,




³J = 5.3, NH); 7.45 (s, 2H, H-8,10-julolidine); 8.03 (t, 1H, ⁴J = 0.5, HC=C). ¹³C NMR (125.7 MHz,


CDCl₃): 21.07 (CH₂-3,6-julolidine); 27.53 (CH₂-4,5-julolidine); 29.92 (CH₂N); 50.13 (CH₂-2,7-julolidine); 71.94 (HC≡C); 79.10 (C≡CH); 92.44 (HC=C-CN); 118.61 (C-9-julolidine); 119.26 (CN); 120.91 (C-4a,4c-julolidine); 131.19 (CH-8,10-julolidine); 147.13 (C-4b-julolidine); 152.89 (HC=C-CN); 162.33 (CO). HRMS: calculated for C₁₉H₂₀ON₃ [M+H]⁺: 306.1601; found: 306.1602. Anal. calcd for C₁₉H₁₉N₃O: C, 74.73; H, 6.27; N, 13.76. Found: C, 74.54; H, 6.21; N, 13.57.

(E)-2-Cyano-3-[4-(dimethylamino)phenyl]-N-(prop-2-yn-1-yl)acrylamide (VII)

Yellow solid (1.20 g, 95%) was obtained following the general procedure. *R_f* = 0.26 (hexane/ethyl acetate, 7/3) ¹H NMR (600.1 MHz, CDCl₃): 2.28 (t, 1H, ⁴*J* = 2.6, HC≡C); 3.10 (s, 6H, (CH₃)₂N); 4.20 (dd, 2H, ³*J* = 5.3, ⁴*J* = 2.6, CH₂N); 6.43 (bt, 1H, ³*J* = 5.3, NH); 6.72 (m, 2H, H-*m*-C₆H₄NMe₂); 7.88 (m, 2H, H-*o*-C₆H₄NMe₂); 8.16 (s, 1H, HC=C). ¹³C NMR (150.9 MHz, CDCl₃): 29.98 (CH₂N); 40.15 (CH₃N); 72.06 (HC≡C); 78.92 (C≡CH); 94.82 (HC=C-CN); 111.75 (CH-*m*-C₆H₄NMe₂); 118.64 (CN); 119.79 (C-*i*-C₆H₄NMe₂); 133.56 (CH-*o*-C₆H₄NMe₂); 153.01 (HC=C-CN); 153.11 (C-*p*-C₆H₄NMe₂); 161.77 (CO). HRMS for C₁₅H₁₅N₃NaO: [M+Na]⁺ calculated 276.1107, found 276.1107. Anal. calcd for C₁₅H₁₅N₃O: C, 71.13; H, 5.97; N, 16.59. Found: C, 70.74; H, 5.92; N, 16.29.



General procedure for the synthesis of the FMR-modified deoxycytidines using the Sonogashira coupling



Dry DMF (4 ml) was added to a flask containing 5-iodo-2'-deoxycytidine **VIII** (176 mg, 0.5 mmol), corresponding acetylene **VI** or **VII** (0.55 mmol), PdCl₂(PPh₃)₂ (18 mg, 5% mol), CuI (5 mg, 5% mol) and the mixture was purged and refilled with argon for 3–4 times. Triethylamine (0.21 ml, 1.5 mmol) was added via syringe and the mixture was stirred at 80 °C until the complete consumption of the


starting nucleoside as monitored by TLC (CH₂Cl₂ / MeOH, 9/1). The mixture was concentrated on a rotavap; the crude products were purified by column chromatography (MeOH in dichloromethane, 5→15%).

(E)-N-[3-(2'-Deoxycytidine-5-yl)prop-2-yn-1-yl]-2-cyano-3-(julolidine-9-yl)acrylamide (dC^{VJ}, 3a)

Yellow solid (233 mg, 88%) was obtained following the general procedure). *R_f* = 0.20 (dichloromethane/MeOH, 9/1).

¹H NMR (500.0 MHz, DMSO-*d*₆): 1.86 (m, 4H, H-3,6-julolidine); 1.97 (ddd, 1H, *J*_{gem} = 13.2, *J*_{2'b,1'} = 7.2, *J*_{2'b,3'} = 6.0, H-2'b); 2.13 (ddd, 1H, *J*_{gem} = 13.2, *J*_{2'a,1'} = 6.0, *J*_{2'a,3'} = 3.4, H-2'a); 2.67 (m, 4H, H-4,5-julolidine); 3.31 (m, 4H, H-2,7-julolidine); 3.54, 3.60 (2 × ddd, 2 × 1H, *J*_{gem} = 12.0, *J*_{5',OH} = 5.2, *J*_{5',4'} = 3.6, H-5'); 3.78 (q, 1H, *J*_{4',3'} = *J*_{4',5'} = 3.6, H-4'); 4.19 (m, 1H, H-3'); 4.22 (d, 2H, *J* = 5.3, CH₂N); 5.06 (t, 1H, *J*_{OH,5'} = 5.2, OH-5'); 5.20 (d, 1H, *J*_{OH,3'} = 4.2, OH-3'); 6.11 (dd, 1H, *J*_{1',2'} = 7.2, 6.0, H-1'); 6.87 (bs, 1H, NH_aH_b); 7.44 (s, 2H, H-8,10-julolidine); 7.82 (bs, 1H, NH_aH_b); 7.84 (s, 1H, HC=C); 8.13 (s, 1H, H-6); 8.41 (t, 1H, *J* = 5.3, NH).


¹³C NMR (125.7 MHz, DMSO-*d*₆): 21.07 (CH₂-3,6-julolidine); 27.53 (CH₂-4,5-julolidine); 30.38 (CH₂N); 40.98 (CH₂-2'); 49.54 (CH₂-2,7-julolidine); 61.23 (CH₂-5'); 70.37 (CH-3'); 74.41 (cyt-C≡C-CH₂-); 85.53 (CH-1'); 87.66 (CH-4'); 89.55 (C-5); 92.50 (cyt-C≡C-CH₂-); 93.79 (HC=C-CN); 117.68 (C-9-julolidine); 118.73 (CN); 120.65 (C-4a,4c-julolidine); 130.62 (CH-8,10-julolidine); 144.01 (CH-6); 147.08 (C-4b-julolidine); 151.06 (HC=C-CN); 153.64 (C-2); 162.69 (CONH); 164.69 (C-4). HRMS for C₂₈H₃₀O₅N₆Na: [M+Na]⁺ calculated 553.2170, found 553.2170.



(E)-N-[3-(2'-Deoxycytidine-5-yl)prop-2-yn-1-yl]-2-cyano-3-[4-(dimethylamino)phenyl]acrylamide (dC^{VDP}, 3b)

Yellow solid (209 mg, 87%) was obtained following the general procedure). *R_f* = 0.19 (dichloromethane / MeOH, 9/1).

¹H NMR (500.0 MHz, DMSO-*d*₆): 1.97 (ddd, 1H, *J*_{gem} = 13.2, *J*_{2'b,1'} = 7.3, *J*_{2'b,3'} = 6.0, H-2'b); 2.13 (ddd, 1H, *J*_{gem} = 13.2, *J*_{2'a,1'} = 6.0, *J*_{2'a,3'} = 3.6, H-2'a); 3.06 (s, 6H, (CH₃)₂N); 3.54, 3.60 (2 × ddd, 2 × 1H, *J*_{gem} = 11.9, *J*_{5',OH} = 5.1, *J*_{5',4'} =




3.6, H-5'); 3.78 (q, 1H, *J*_{4',3'} = *J*_{4',5'} = 3.6, H-4'); 4.19 (m, 1H, H-3'); 4.24 (d, 2H, *J* = 5.2, CH₂N); 5.07 (t,

1H, $J_{\text{OH},5'} = 5.1$, OH-5'); 5.21 (d, 1H, $J_{\text{OH},3'} = 4.2$, OH-3'); 6.11 (dd, 1H, $J_{1',2'} = 7.3, 6.0$, H-1'); 6.83 (m, 2H, H-*m*-C₆H₄NMe₂); 6.87, 7.82 (2 × bs, 2 × 1H, NH₂); 7.88 (m, 2H, H-*o*-C₆H₄NMe₂); 8.00 (s, 1H, HC=C); 8.13 (s, 1H, H-6); 8.54 (t, 1H, $J = 5.2$, NH). ¹³C NMR (125.7 MHz, DMSO-*d*₆): 30.42 (CH₂N); 39.78 (CH₃N); 40.99 (CH₂-2'); 61.24 (CH₂-5'); 70.38 (CH-3'); 74.50 (cyt-C≡C-CH₂-); 85.55 (CH-1'); 87.66 (CH-4'); 89.55 (C-5); 92.32 (cyt-C≡C-CH₂-); 96.18 (HC=C-CN); 111.88 (CH-*m*-C₆H₄NMe₂); 118.31 (CN); 118.80 (C-*i*-C₆H₄NMe₂); 133.09 (CH-*o*-C₆H₄NMe₂); 144.07 (CH-6); 151.23 (HC=C-CN); 153.31 (C-*p*-C₆H₄NMe₂); 153.65 (C-2); 162.46 (CONH); 164.68 (C-4). HRMS for C₂₄H₂₆N₆O₅Na: [M+Na]⁺ calculated 501.1857, found 501.1857

5'-*O*-Triphosphorylation of nucleosides 3a and 3b

(*E*)-*N*-[3-(2'-deoxycytidine-5-yl)prop-2-yn-1-yl]-2-cyano-3-(julolidine-9-yl)acrylamide 5'-*O*-triphosphate (dC^{VJ}TP, 4a)

Dry trimethyl phosphate (2 ml) was added to an argon-purged flask containing nucleoside dC^{VJ} (112 mg, 0.21 mmol). The resulting solution was cooled down to 0 °C and a solution of POCl₃ (32 μL, 0.34 mmol) in trimethyl phosphate (0.5 mL)




was added dropwise. After 3 hours stirring at 0 °C, a solution of (*n*-Bu₃NH)₂H₂P₂O₇ (522 mg, 0.95 mmol) and *n*-Bu₃N (0.23 mL, 0.95 mmol) in dry DMF (2.5 mL) was added. The solution was stirred for another 60 min at 0 °C and then quenched by the addition of 1M TEAB (3 mL). The mixture was concentrated on a rotavap; the residue was co-evaporated with distilled water three times. After that the crude mixture was diluted with water to a total volume of ca. 15 mL and unreacted nucleoside was separated by filtration. The aqueous solution was purified by semi-preparative HPLC using a linear gradient of methanol (5–100%) in 0.1 M TEAB buffer. The appropriate fractions were combined and evaporated on a rotavap. The viscous orange oil was co-evaporated with distilled water three times. The product was converted to sodium salt on an ion-exchange column (Dowex 50WX8 in Na⁺ cycle) and freeze-dried. The title compound was obtained as orange solid (16 mg, 9%). ¹H NMR (500.0 MHz, D₂O, pD = 7.1, phosphate buffer, ref(dioxane) = 3.75 ppm): 1.69 (bm, 4H, H-3,6-julolidine); 2.21 (dt, 1H, $J_{\text{gem}} = 13.9, J_{2'b,1'} = J_{2'b,3'} = 6.4$, H-2'b); 2.41 (m, 5H, H-2'a, H-4,5-julolidine); 3.08 (m, 4H, H-2,7-julolidine); 4.14-4.21 (m, 3H, H-4',5'); 4.27, 4.33 (2 × d, 2 × 1H, $J_{\text{gem}} = 18.2$, CH₂N); 4.55 (m, 1H, H-3'); 6.07 (t, 1H, $J_{1',2'} = 6.4$, H-1'); 7.01 (bs, 2H, H-8,10-julolidine); 7.52 (s, 1H, HC=C); 7.99 (s, 1H, H-

6). ^{13}C NMR (125.7 MHz, D_2O , pD = 7.1, phosphate buffer, ref(dioxane) = 69.3 ppm): 23.15 (CH_2 -3,6-julolidine); 29.69 (CH_2 -4,5-julolidine); 33.07 (CH_2N); 41.86 (CH_2 -2'); 52.42 (CH_2 -2,7-julolidine); 67.89 (d, $J_{\text{C,P}} = 5.4$, CH_2 -5'); 72.92 (CH -3'); 75.68 (cyt- $\text{C}\equiv\text{C}$ - CH_2 -); 88.08 (d, $J_{\text{C,P}} = 8.6$, CH -4'); 89.11 (CH -1'); 92.20 (C-5); 94.63 (cyt- $\text{C}\equiv\text{C}$ - CH_2 -); 95.16 ($\text{HC}=\text{C}$ -CN); 120.14 (C-9-julolidine); 121.91 (CN); 123.46 (C-4a,4c-julolidine); 133.98 (CH -8,10-julolidine); 147.48 (CH -6); 150.62 (C-4b-julolidine); 155.04 ($\text{HC}=\text{C}$ -CN); 158.33 (C-2); 167.63 (C-4); 168.10 (CONH). ^{31}P NMR (202.4 MHz, D_2O , pD = 7.1, ref(phosphate buffer) = 2.35 ppm): -21.04 (dd, $J = 19.1, 18.9$, P_β); -10.16 (d, $J = 18.9$, P_α); -6.86 (d, $J = 19.1$, P_γ). HRMS for $\text{C}_{28}\text{H}_{30}\text{O}_{14}\text{N}_6\text{Na}_2\text{P}_3$: $[\text{M}+2\text{Na}+\text{H}]^-$ calculated 813.0823; found 813.0825.

(E)-N-[3-(2'-Deoxycytidine-5-yl)prop-2-yn-1-yl]-2-cyano-3-[4-(dimethylamino)phenyl]acrylamide 5'-O-triphosphate (dC^{VDP}TP, 4b)

Dry trimethyl phosphate (3 ml) was added to an argon-purged flask containing nucleoside dC^{VDP} (165 mg, 0.345 mmol). The resulting solution was cooled down to 0 °C and a solution of POCl_3 (57 μL , 0.61 mmol) in trimethyl phosphate (1 mL) was



added dropwise. After 3 hours stirring at 0 °C, a solution of (*n*- Bu_3NH) $_2\text{H}_2\text{P}_2\text{O}_7$ (850 mg, 1.55 mmol) and *n*- Bu_3N (0.37 mL, 1.55 mmol) in dry DMF (4.5 mL) was added. The solution was stirred for another 60 min at 0 °C and then quenched by the addition of 1M TEAB (5 mL). The mixture was concentrated on a rotavap; the residue was co-evaporated with distilled water three times. After that the crude mixture was diluted with water to a total volume of ca. 20 mL and unreacted nucleoside was separated by filtration. The aqueous solution was purified by semi-preparative HPLC using a linear gradient of methanol (5–100%) in 0.1 M TEAB buffer. The appropriate fractions were combined and evaporated on a rotavap. The viscous yellow oil was co-evaporated with distilled water three times. The product was converted to sodium salt on an ion-exchange column (Dowex 50WX8 in Na^+ cycle) and freeze-dried. The title compound was obtained as yellow solid (25 mg, 9%). ^1H NMR (600.1 MHz, D_2O , pD = 7.1, phosphate buffer, ref(dioxane) = 3.75 ppm): 2.24 (ddd, 1H, $J_{\text{gem}} = 14.0$, $J_{2'b,1'} = 6.8$, $J_{2'b,3'} = 6.2$, H-2'b); 2.40 (ddd, 1H, $J_{\text{gem}} = 14.0$, $J_{2'a,1'} = 6.2$, $J_{2'a,3'} = 4.6$, H-2'a); 2.94 (s, 6H, $(\text{CH}_3)_2\text{N}$); 4.16-4.23 (m, 3H, H-4',5'); 4.29, 4.34 (2 \times d, 2 \times 1H, $J_{\text{gem}} = 17.8$, CH_2N); 4.56 (m, 1H, H-3'); 6.12 (dd, 1H, $J_{1,2'} = 6.8$, 6.2, H-1'); 6.55 (m, 2H, H-*m*- $\text{C}_6\text{H}_4\text{NMe}_2$); 7.63 (m, 2H, H-*o*- $\text{C}_6\text{H}_4\text{NMe}_2$); 7.77 (s, 1H,

HC=C); 8.03 (s, 1H, H-6). ^{13}C NMR (150.9 MHz, D_2O , pD = 7.1, phosphate buffer, ref(dioxane) = 69.3 ppm): 33.15 (CH_2N); 41.83 ($\text{CH}_2\text{-2'}$); 41.98 (CH_3N); 67.79 (d, $J_{\text{C,P}} = 5.3$, $\text{CH}_2\text{-5'}$); 72.72 (CH-3'); 75.90 (cyt- $\text{C}\equiv\text{C-CH}_2\text{-}$); 88.11 (d, $J_{\text{C,P}} = 8.7$, CH-4'); 88.99 (CH-1'); 94.68 (C-5); 94.86 (cyt- $\text{C}\equiv\text{C-CH}_2\text{-}$); 95.34 (HC=C-CN); 114.18 ($\text{CH-}m\text{-C}_6\text{H}_4\text{NMe}_2$); 121.20 ($\text{C-}i\text{-C}_6\text{H}_4\text{NMe}_2$); 121.27 (CN); 136.56 ($\text{CH-}o\text{-C}_6\text{H}_4\text{NMe}_2$); 147.56 (CH-6); 155.75 (HC=C-CN); 156.50 ($\text{C-}p\text{-C}_6\text{H}_4\text{NMe}_2$); 158.51 (C-2); 167.71 (C-4); 167.80 (CONH). ^{31}P NMR (202.3 MHz, D_2O , pD = 7.1, ref(phosphate buffer) = 2.35 ppm): -21.62 (dd, $J = 19.8, 18.6$, P_β); -11.12 (d, $J = 18.6$, P_α); -5.96 (d, $J = 19.8$, P_γ). HRMS for $\text{C}_{24}\text{H}_{26}\text{O}_{14}\text{N}_6\text{Na}_2\text{P}_3$: $[\text{M}+2\text{Na}+\text{H}]^-$ calculated 761.0521 found 761.0524.

D. Enzymatic incorporation of modified dNTPs into DNA

Materials and methods

Synthetic oligonucleotides (primers and templates for PEX and NEAR, Table S1) were purchased from Generi Biotech (Czech Republic). Double-stranded 100bp DNA ladder was purchased from New England Biolabs. Single stranded DNA ladder (10, 20, 50, 98 bases) was prepared using synthetic oligonucleotides **L10**, **L20**, **L50** and **T1R** (Table S1) as described previously.⁵⁶ DNA polymerase Vent(exo−), nicking enzyme Nt.BstNBI, corresponding reaction buffers, as well as natural nucleoside triphosphates (dATP, dCTP, dGTP, dTTP) were purchased from New England Biolabs. KOD XL DNA polymerase and corresponding reaction buffer were obtained from Merck Millipore. Streptavidin magnetic particles were obtained from Roche. All solutions for biochemical reactions were prepared using Milli-Q water. Primers for analytical primer extension experiments were labeled using T4 polynucleotide kinase (New England Biolabs) and [$\gamma^{32}\text{P}$]-ATP (Institute of Isotopes Co., Ltd.; Hungary) according to standard techniques. Radioactive gels were visualized by phosphorimaging using Storage Phosphor Screens (GE Healthcare) and Typhoon 9410 imager (Amersham Biosciences). Mass spectra of oligonucleotides were measured by MALDI-TOF, on UltrafleXtreme MALDI-TOF/TOF mass spectrometer (Bruker Daltonics, Germany), with 1 kHz smartbeam II laser.

Analytical primer extension

The reaction mixture (20 μL) contained 5'- ^{32}P -labelled primer (3 μM , 1 μL), unlabelled primer (100 μM , 0.77 μL), template (100 μM , 0.8 μL), corresponding DNA polymerase (0.22–0.23 U), either natural or modified dNTPs (4 mM each, 0.4 μL) and reaction buffer (10 \times , 2 μL) supplied by the manufacturer with the enzyme. The reaction mixture was incubated at 60 $^{\circ}\text{C}$ for 40 min. The reaction was stopped by the addition of PAGE stop solution (40 μL ; 80% [v/v] formamide, 20mM EDTA, 0.025% [w/v] bromophenol blue, 0.025% [w/v] xylene cyanol) and heated at 95 $^{\circ}\text{C}$ for 5 min. Aliquots (3 μL) were subjected to vertical electrophoresis in 12.5% denaturing polyacrylamide gel containing 1 \times TBE buffer (pH 8.0) and 7M urea at 42 mA for 50 min. The gel was dried in vacuo (80 $^{\circ}\text{C}$, 70 min) and visualized by phosphor imaging autoradiography.

Semi-preparative primer extension with magnetic separation

The reaction mixture (100 μL) containing KOD XL DNA polymerase (2.5 U/ μL , 0.45 μL), 10 \times concentrate of the KOD reaction buffer provided by the manufacturer of the enzyme (10 μL),

biotinylated template (100 μ M, 4 μ L), primer (100 μ M, 4 μ L), dNTPs (dGTP, dTTP, dATP, **dC^XTP**; 4 mM each, 5 μ L) was incubated at 60 °C for 40 minutes. The reaction was stopped by cooling to 4 °C. Streptavidine magnetic particles (120 μ l) were washed with binding buffer (3 \times 300 μ l, 10mM Tris, 1mM EDTA, 100mM NaCl, pH 7.5). The PEX solution (100 μ L) and binding buffer (100 μ l) were added to the magnetic beads. The mixture was incubated in a thermal mixer for 35 min at 15 °C and 1200 rpm. Then the magnetic beads were washed with wash buffer (3 \times 300 μ l, 10mM Tris, 1mM EDTA, 500mM NaCl, pH 7.5) and water (4 \times 300 μ l). Then water (100 μ l) was added and the sample was denatured for 2 min at 40 °C and 900 rpm. The beads were separated and the solution containing ssDNA was transferred into a clean vial. Concentration of the resulting DNA solutions was determined on a NanoDrop. The product was analysed by MALDI-TOF mass spectrometry.

Nicking enzyme amplification reaction (NEAR) with modified dNTPs on analytical scale

The reaction mixture (50 μ L) contained the template (0.125 μ M), primer (0.125 μ M), modified **dC^XTP** (187.5 μ M), natural dNTPs (dGTP, dTTP, dATP; 125 μ M each), 1 \times ThermoPol buffer (10 mM KCl, 10 mM (NH₄)₂SO₄, 20 mM Tris-HCl/pH 8.8/, 0.1% Triton-X-100, and 2mM MgSO₄), and 0.5 \times NEBuffer 3 (50mM NaCl, 25 mM Tris-HCl/pH 7.9/, 5 mM MgCl₂, and 0.5 mM DTT), Vent(exo-) DNA polymerase (7.5 U) and nickase Nt.BstNBI (30 U). The reaction mixture was incubated in a thermal mixer at 55 °C, 400 rpm for 3 h. The reaction was stopped by cooling to 4 °C. The products were analyzed by agarose gel electrophoresis using 4% agarose gels stained with GelRed™ (Biotium). Samples for electrophoresis were prepared by mixing 1.6 μ L of TrackIt™ Cyan/Orange loading buffer (Invitrogen) and 8 μ L of the reaction mixture or ssDNA ladder. The gel was run for 60 min at 120 V and imaged using electronic dual wave transilluminator equipped with UltraCam 8gD digital imaging system (Ultra-Lum). For MALDI-TOF mass spectrometry analysis the reaction mixtures were purified on Illustra MicroSpin G-25 columns (GE Healthcare) to remove the unincorporated nucleotides and buffer salts.

Nicking enzyme amplification reaction (NEAR) with dC^{VDP}TP on semi-preparative scale

The reaction mixture (500 μ L) contained the template (0.125 μ M), primer (0.125 μ M), modified **dC^{VDP}TP** (187.5 μ M), natural dNTPs (dGTP, dTTP, dATP; 125 μ M each), 1 \times ThermoPol buffer (10 mM KCl, 10 mM (NH₄)₂SO₄, 20 mM Tris-HCl/pH 8.8/, 0.1% Triton-X-100, and 2 mM MgSO₄), and 0.5 \times NEBuffer 3 (50mM NaCl, 25 mM Tris-HCl/pH 7.9/, 5 mM MgCl₂, and 0.5 mM DTT), Vent(exo-) DNA polymerase (50 U) and nickase Nt.BstNBI (280 U). The reaction mixture was incubated at 55

°C, 400 rpm for 3 h. After that the reaction was stopped by cooling to 4 °C, the solution was concentrated on a vacuum concentrator to approximately 100 µL. The viscous concentrate was subjected to HPLC purification on a XBridge OST C18 Column (Waters; 2.5 µm particle size, 4.6 mm × 50mm). A linear gradient of triethylammonium acetate buffer (TEAA, pH = 7.0) and acetonitrile with flow rate 1 mL/min was used. Mobile phase A corresponds to 0.1 M TEAA in HPLC-grade water, mobile phase B to acetonitrile/0.1 M TEAA in HPLC-grade water 20/80 (v/v). The gradient started with 60% mobile phase A and 40% mobile phase B, going linearly to 80% mobile phase B in 53 min. The fractions containing the product were combined and evaporated on a vacuum concentrator. The residue was dissolved in a known volume of water and UV absorbance was measured on a Nanodrop. The products were analyzed by MALDI-TOF mass spectrometry.

Polymerase chain reaction (PCR)

The reaction mixture (10 µL) contained KOD XL DNA polymerase (2.5 U/µL, 0.1 µL), KOD XL reaction buffer supplied by the manufacturer (10×, 1 µL), primers **P1R** and **P2R** (10 µM; 1µL of each), 98-mer template **T1R** (1 µM, 0.25 µL). The amounts of dNTPs depend on whether only natural dNTPs or modified **dC^xTP** together with the three remaining natural dNTPs were incorporated. The following amounts were used: positive control – four natural dNTPs (2mM of each, 0.15 µL); negative control – three natural dNTPs (10 mM of dGTP, dTTP, and dATP, 0.6 µL); modified **dC^xTPs** – **4a** or **4b** with three natural dNTPs (10 mM of each, 0.6 µL). After the initial denaturation for 3 min at 94 °C, 40 PCR cycles were run under the following conditions: denaturation for 1 min at 94 °C, annealing for 1 min at 51°C, extension for 2 min at 72°C. These PCR process was terminated with a final extension step for 6 min at 72 °C. The reaction was stopped by cooling to 4 °C. The products were analyzed by agarose gel electrophoresis using 2% agarose gel stained with GelRed™ (Biotium). Samples for electrophoresis were prepared by mixing 1 µL of 6× DNA Loading Dye (Thermo Scientific) and 5 µL of the reaction mixture. The gel was run for 70 min at 120 V and imaged using electronic dual wave transilluminator equipped with UltraCam 8gD digital imaging system (Ultra-Lum).

E. UV-Vis and Fluorescence measurements

General notes

Spectroscopy grade solvents (DMSO, ethylene glycol, glycerol) were purchased from Sigma Aldrich and Alfa Aesar. Absorption coefficients of natural and modified ODNs (ϵ_{260}) were estimated using the OligoCalc.^{S7} The absorption of the modified **dC^x** analogues at 260 nm was assumed to be identical with dC. UV-visible spectra of individual compounds were measured on a Cary 100 UV-Vis spectrometer (Agilent Technologies). UV-vis spectra of oligonucleotides were measured on a Nanodrop 1000 spectrophotometer (Thermo Scientific). Fluorescence spectra were measured on a Jasco 6600 or Fluorolog (Horiba) spectrofluorimeters.

Fluorescence of FMRs in a gradient of viscosity

For the measurements of fluorescence in the gradient of viscosity (ethylene glycol / glycerol) we used procedure described elsewhere^{S1} with minor modifications. Solutions of different viscosities were prepared by mixing known volumes of pre-stained EG, EG and glycerol. Stock solutions of FMRs **1a**, **1b**, **3a** and **3b** were prepared in DMSO (1–5 mg per 0.5 mL DMSO). Pre-stained ethylene glycol was prepared by adding a small volume of the DMSO stock solution (10–50 μ L) to 10 mL of ethylene glycol; absorbance of the resulting solutions was measured on a UV-Vis spectrometer. Pre-stained ethylene glycol, ethylene glycol and glycerol were mixed in proportions shown in table S3.

Table S3. Preparation of the samples for measurement of fluorescence in the gradient of viscosity

Viscosity (mPa · s)	Components (mL) ^a		
	pre-stained ethylene glycol ^b	ethylene glycol ^b	glycerol
74.0	x	3.0–x	2.0
112.2	x	2.5–x	2.5
170.2	x	2.0–x	3.0
258.1	x	1.5–x	3.5
391.4	x	1.0–x	4.0

Footnotes: **a**: total volume of each sample was 5 mL. **b**: x is the volume of pre-stained ethylene glycol (mL) needed to give absorbance 0.05 at λ_{\max} in the final 5mL solution; x was calculated for each compound from the UV-vis absorption spectra of pre-stained EG by formula: $x \text{ (mL)} = (0.05 \times 5 / A_{\text{PS-EG}})$ where $A_{\text{PS-EG}}$ is the absorbance of pre-stained EG at λ_{\max} .

Glycerol was heated on a water bath to 55–60 °C to allow for better pipetting. Solutions were prepared in 15 mL plastic tubes and mixed thoroughly on a tube roller for 30–60 minutes. Thorough mixing was

crucial so the tubes were watched over this time. Fluorescence spectra were recorded at room temperature (22–23 °C) in quartz cuvettes (internal volume 1.4 mL). Samples were excited at their absorption maxima. Intensity of fluorescence at the emission maximum was measured for each sample; within each series, the intensity of fluorescence was normalized to the intensity of fluorescence of the less viscous solution (I_F for 74.0 mPa·s = 1). Preparations and measurements were triplicated. Förster–Hoffmann plot was obtained by plotting $\log F$ vs logarithm of viscosity ($\log \eta$).

Fluorescence titration experiments

Titration were performed in a 100 μ L quartz cuvette at room temperature (22 °C). Initial solution (120 μ L) contained 1 μ M ssDNA probe **ON1** (Table S2) in PBS (10 mM phosphate buffer pH 7.4; 100 mM NaCl). Excitation wavelength was 430 nm. Aliquots (0.2 μ L) of SSB, BSA or PBS-glycerol were added; the solution was carefully mixed with a pipette and equilibrated for 2–3 minutes before the fluorescence spectrum was recorded.

Solutions for titration were prepared as follows.

SSB

Single-strand Binding Protein from *Escherichia coli* (Sigma-Aldrich) was used as supplied (Solution in 20 mM Tris-HCl, pH 8.0, 0.5 M NaCl, 0.1 mM EDTA, 0.1 mM DTT, 50% glycerol). The concentration of the supplied solution determined on a Nanodrop ($\epsilon_{280} = 30250 \text{ M}^{-1} \text{ cm}^{-1}$ for SSB monomer^{S8}) was ca. 50 μ M (SSB tetramer).

BSA

Bovine serum albumin (New England Biolabs) was diluted to the same concentration as SSB (50 μ M) in PBS (10 mM phosphate buffer pH = 7.4; 100 mM NaCl). $\epsilon_{280} = 43800 \text{ M}^{-1} \text{ cm}^{-1}$.^{S9}

PBS-glycerol



PBS-glycerol was prepared by mixing 100 mM phosphate buffer pH = 7.4 (100 μ L), 1 M NaCl (100 μ L), water (300 μ L) and glycerol (500 μ L).

F. References


- S1.** J. Sutharsan, D. Lichlyter, N. E. Wright, M. Dakanali, M. A. Haidekker and E. A. Theodorakis, *Tetrahedron*, 2010, **66**, 2582–2588.
- S2.** H. Wang, Z. Lu, S. J. Lord, K. A. Willets, J. A. Bertke, S. D. Bunge, W. E. Moerner and R. J. Twieg, *Tetrahedron*, 2007, **63**, 103–114.
- S3.** A. Bringhen and U. Huber, 6416746 B1, US, 2002.
- S4.** U. P. Kreher, A. E. Rosamilia, C. L. Raston, J. L. Scott and C. R. Strauss, *Org. Lett.*, 2003, **5**, 3107–3110.
- S5.** Y. Matvieiev, I. Karpenko, A. Kulinich, A. Ryabitskii, V. Pivovarenko, S. Shishkina, O. Shishkin and V. Kalchenko, *Tetrahedron Lett.*, 2011, **52**, 3922–3925.
- S6.** P. Ménová, V. Raindlová and M. Hocek, *Bioconjugate Chem.*, 2013, **24**, 1081–1093.
- S7.** W. A. Kibbe, *Nucleic Acids Res.*, 2007, **35**, W43–W46.
- S8.** K. R. Williams, E. K. Spicer, M. B. LoPresti, R. A. Guggenheimer and J. W. Chase, *J. Biol. Chem.*, 1983, **258**, 3346–3355.
- S9.** T. Peters, *The Plasma Proteins.*, Academic Press., 1975, pp 133–181.

G. Copies of the NMR spectra

^1H and ^{13}C spectra of intermediate **V**



¹H and APT spectra of intermediate VI




DZIUBA DZ032
¹H NMR in CDCl₃
 06-12-12 RA

```

NAME DZIUBA_DZ032
EXPNO 1
PROCNO 1
Date_ 20121206
Time 17.07
INSTRUM spect
PROBHD 5 mm TXI 1H-13
PULPROG zg30
TD 71222
SOLVENT CDCl3
NS 32
DS 0
SWH 7122.507
FIDRES 0.100004
AQ 4.9999046
RG 11.3
DM 70.200
DE 6.00
TE 298.0
D1 1.00000000
TD0 1
    
```

```

CHANNEL f1
NUC1 1H
P1 8.00
PL1 0.00
PL1W 8.54041386
SFO1 499.9514566
SI 131072
SF 499.9500079
WDW no
SSB 0
LB 0
GB 0
PC 20.00
    
```



DZIUBA DZ032
 APT in CDCl₃
 06-12-12 RA

```


NAME DZIUBA_DZ032
EXPNO 2
PROCNO 1
Date_ 20121206
Time 19.40
INSTRUM spect
PROBHD 5 mm TXI 1H-13
PULPROG mod
TD 65536
SOLVENT CDCl3
NS 1795
DS 4
SWH 31446.541 Hz
FIDRES 0.478836 Hz
AQ 1.0403983 sec
RG 32788
DM 15.000 usec
DE 6.50 usec
TE 298.0 K
CNST2 145.0000000
CNST11 0.0000000
D1 2.00000000 sec
D20 0.00689655 sec
TD0 1
    
```

```

CHANNEL f1
NUC1 13C
P1 15.00 usec
P2 30.00 usec
PL1 0.00 dB
PL1W 81.5388629 W
SFO1 125.7216125 MHz

CHANNEL f2
CPDPRG2 waltz16
NUC2 1H
PCPD2 80.00 usec
PL2 1.00 dB
PL12 19.78 dB
PL1W 6.78389168 W
PL2W 0.89663625 W
SFO2 499.9519996 MHz
SI 131072
SF 125.712525 MHz
WDW EM
SSB 0
LB 3.00 Hz
GB 0
PC 1.00
    
```

¹H and APT spectra of intermediate VII




DZIUBA DZ019
¹H NMR in CDCl₃
 27-11-12 RA

```

NAME      DZIUBA_DZ019
EXPNO     1
PROCNO    1
Date_     20121127
Time      13.59
INSTRUM   spect
PROBHD    5 mm CPTC1 1H-
PULPROG   zg30
TD         84114
SOLVENT   CDCl3
NS         8
DS         0
SWH        8417.509
FIDRES     0.100001
AQ         4.9999857
RG         16
DW         59.400
DE         10.00
TE         298.0
D1         0.0000000
TD0        1

----- CHANNEL f1 -----
NUC1      1H
P1        10.00
PL1       0.10
PL1W      5.29101372
SFO1      600.1339008
SI        131072
SF        600.1300165
WDW        no
SSB        0
LB         0.00
GB         0
PC         40.00
    
```



DZIUBA DZ019
 APT in CDCl₃
 27-11-12 RA


```

NAME      DZIUBA DZ019
EXPNO     2
PROCNO    1
Date_     20121127
Time      14.00
INSTRUM   spect
PROBHD    5 mm CPTC1 1H-
PULPROG   mod
TD         7572
SOLVENT   CDCl3
NS         20
DS         4
SWH        37878.788 Hz
FIDRES     0.500037 Hz
AQ         0.9999764 sec
RG         2050
DW         13.200 usec
DE         6.00 usec
TE         298.0 K
D1         1.0000000
D11        2.0000000 sec
D20        0.00689655 sec
TD0        1

----- CHANNEL f1 -----
NUC1      13C
P1        12.00 usec
P2        24.00 usec
PL1       -1.40 dB
PL1W      107.48843231 W
SFO1      150.9194083 MHz

----- CHANNEL f2 -----
CPDPRG2   waltz16
NUC2      1H
PCPD2     80.00 usec
PL2       7.00 dB
PL2W      25.00 dB
PL3W      6.81614837 W
PL3W      0.10002664 W
SFO2      600.1324005 MHz
SF        1310.72
SF        150.9028171 MHz
WDW        EM
SSB        0
LB         1.00 Hz
GB         0
PC         1.00
    
```

¹H and APT spectra of nucleoside dC^{VJ} (3a)




DZIUBA DZ055
1H NMR in DMSO-d6
18-01-13 RA

```

NAME      DZIUBA_DZ055
EXPNO     1
PROCNO    1
Date_     20130118
Time      16.38
INSTRUM   spect
PROBHD    5 mm CPBBO BB-
PULPROG   zg30
TD         71222
SOLVENT   DMSO
NS         32
DS         0
SWH        7122.507
FIDRES     0.150004
AQ          4.9999046
RG          11.3
DW          70.200
DE           6.00
TE          298.0
D1          1.00000000
TD0         1
    
```

```

----- CHANNEL f1 -----
NUC1       1H
P1         12.00
P2         -2.20
PL1        14.17355919
SF01       499.9534566
SI         131072
SF         499.9499998
WDW        no
SSB         0
LB          0
GB          0
PC         10.00
    
```



DZIUBA DZ055
APT in DMSO-d6
18-01-13 RA

```



NAME      DZIUBA_DZ055
EXPNO     2
PROCNO    1
Date_     20130118
Time      16.54
INSTRUM   spect
PROBHD    5 mm CPBBO BB-
PULPROG   gpmf
TD         65532
SOLVENT   DMSO
NS         348
DS         4
SWH        31448.541 Hz
FIDRES     0.479838 Hz
AQ          1.0420983 sec
RG          377.8
DW          15.500 usec
DE           5.50 usec
TE          298.0 K
CNST2     145.0000000
CNST11    1.0000000
D1         2.00000000 sec
D20        0.00889655 sec
TD0         1
    
```

```

----- CHANNEL f1 -----
NUC1       13C
P1         10.00 usec
P2         20.00 usec
PL1        3.15 dB
PL1W       29.94771957 W
SF01       125.770135 MHz


----- CHANNEL f2 -----
CPDPRG2   waltz16
NUC2       1H
PCPD2      90.00 usec
PL2        -2.60 dB
PL12       15.50 dB
PL2W       15.5409046 W
PL12W      0.22563570 W
SF02       499.9510998 MHz
SI         131072
SF         125.7125511 MHz
WDW        EM
SSB         0
LB          3.00 Hz
GB          0
PC         1.00
    
```

^1H and APT spectra of nucleoside **dC^{VDP}** (**3b**)



E

¹H, APT and ³¹P spectra of dC^{VJ}TP (4a)




DZIUBA DZ060
1H NMR in D₂O
pD = 7.1, phosphate buffer
05-02-13 RA

```

NAME      DZIUBA_DZ060
EXPNO    100
PROCNO   1
Date_    20130206
Time     10.33
INSTRUM  spect
PROBHD   5 mm CPBBO BB-
PULPROG  zgpg
TD        32768
SOLVENT  D2O
NS        32
DS        2
SWH       8012.820
FIDRES   0.244532
AQ        2.0448356
RG        327.7
DW        62.400
DE        6.50
TE        299.0
D1        2.00000000
D12       0.00002000
TD0       1

----- CHANNEL f1 -----
NUC1      1H
P1        12.00
PL1       -2.20
PL12      49.80
PL1W      14.1735919
PL1W2     0.00009943
SFO1      499.9523458
SI        32768
SF        499.9499412
RGW       8M
RSB       0
LB        0.30
GB        1.00
PC        1.00
    
```



DZIUBA DZ060
APT in D₂O
pD = 7.1, phosphate bui
05-03-13 RA


```

NAME      DZIUBA_DZ060
EXPNO    2
PROCNO   1
Date_    20130206
Time     17.16
INSTRUM  spect
PROBHD   5 mm CPBBO BB-
PULPROG  zgpg
TD        65536
SOLVENT  D2O
NS        17158
DS        4
SWH       30093.020 Hz
FIDRES   0.45622 Hz
AQ        1.0912410 sec
RG        29193
DW        18.650 usec
DE        6.50 usec
TE        296.0 K
CNST2    145.000000
CNST11   1.0000000
D1        2.00000000 sec
D20       0.00699655 sec
TD0       1

----- CHANNEL f1 -----
NUC1      13C
P1        10.00 usec
P2        20.00 usec
PL1       3.55 dB
PL12      29.94771957 W
SFO1      125.762968 MHz


----- CHANNEL f2 -----
CPDPRG2  waltz16
NUC2      1H
PCPD2    80.00 usec
PL2       -2.50 dB
PL12     15.38 dB
PL1W     15.5409846 W
PL1W2    0.22053570 W
SFO2     499.9519968 MHz
SI        131072
SF        125.712153 MHz
RGW       8M
RSB       0
LB        1.00 Hz
GB        1.40
PC        1.40
    
```


¹H, APT and ³¹P spectra of dC^{VDP}TP (4b)




```

DZIUBA DZ030
1H NMR in D2O
pD = 7.1, phosphate buff
19-12-12 RA
*****
NAME      DZIUBA_DZ030
EXPNO    1
PROCNO   1
Date_    20121219
Time     18.26
INSTRUM  spect
PROBHD   5 mm CPTCI 1H-
PULPROG  zg30
TD        56304
SOLVENT  D2O
NS        32
DS        0
SWH       5630.631
FIDRES    0.100004
AQ        4.9998450
RG        45.2
DW        88.800
DE        20.00
TE        298.0
TE        298.0
D1        1.0000000
TD0       1
*****
CHANNEL f1 -----
NUC1      1H
P1        10.00
PL1       8.10
PL1W      5.29101372
SFO1      600.1326118
SI        131072
SF        600.1299501
WDW       EM
SSB       0
GB        0.00
PC        10.00
    
```



```

DZIUBA DZ030
APT in D2O
pD = 7.1, phosphate buffer
19-12-12 RA
*****
NAME      DZIUBA_DZ030
EXPNO    2
PROCNO   1
Date_    20121219
Time     18.30
INSTRUM  spect
PROBHD   5 mm CPTCI 1H-
PULPROG  zgpg30
TD        75712
SOLVENT  D2O
NS        638
DS        4
SWH       37678.789 Hz
FIDRES    0.500037 Hz
AQ        0.9999764 sec
RG        362
DW        13.200 usec
DE        6.00 usec
TE        298.0 K
TE        298.0 K
CNST2    145.000000
CNST11    1.0000000
D1        2.0000000 sec
D20       0.00689655 sec
TD0       1
*****
CHANNEL f1 -----
NUC1      31P
P1        12.00 usec
P2        24.00 usec
PL1       -1.40 dB
PL1W      107.48845821 MHz
SFO1      150.9194683 MHz
*****
CHANNEL f2 -----
CPDPRG2  waltz16
NUC2      1H
PCPD2    80.00 usec
PL2       7.00 dB
PL2W     25.00 dB
PL2W     6.81614637 W
PL2W     0.1080586 W
SFO2     600.1324905 MHz
SI        131072
SF        150.9022923 MHz
WDW       EM
SSB       0
LB        1.00 Hz
GB        0
PC        1.00
    
```



DZIUBA DZ030
 31P(1H) NMR in D2O
 pD = 7.1, phosphate buffer
 20-12-12 RA


```

NAME DZIUBA DZ030
EXPNO 10
PROCNO 1
Date_ 20121220
Time 15.16
INSTRUM spect
PROBHD 5 mm TBO BB-1H
PULPROG zgpg30
TD 65536
SOLVENT D2O
NS 128
DS 4
SWH 81521.742 Hz
FIDRES 1.243923 Hz
AQ 0.4620041 sec
RG 23100
RW 6.153 usec
DE 6.00 usec
TE 298.2 K
D1 2.00000000 sec
D11 0.03000000 sec
TDO

----- CHANNEL f1 -----
NUC1 31P
P1 7.80 usec
PL1 -0.50 dB
PL1W 93.0086257 W
SFO1 202.3282239 MHz


----- CHANNEL f2 -----
CPDPRG2 waltz16
NUC2 1H
PCPD2 80.00 usec
PL2 -2.00 dB
PL2 14.71 dB
PL3 14.71 dB
PL3W 31.94857358 W
PL12W 0.6763436 W
PL13W 0.6763436 W
SFO2 499.8419994 MHz
SF 13101.2
SF 202.3282239 MHz
WDW EM
SSB 0
LB 3.00 Hz
GB 0
PC 1.40
  
```

47494


H. Copies of MALDI spectra

See Table S2 for sequences


ON1




ON2



ON3



ON4



ON5

